| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $949,381 | 2 | 29 |
Sells | $939,970 | 5 | 71 |
| Ciongoli Gregory Austin | director | 2 | $949,381 | 0 | $0 | $949,381 |
| PAKOLA STEVE | Chief Medical Officer | 0 | $0 | 5 | $939,970 | $-939,970 |
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III …
Over the last 12 months, insiders at REGENXBIO Inc. have bought $949,381 and sold $939,970 worth of REGENXBIO Inc. stock.
On average, over the past 5 years, insiders at REGENXBIO Inc. have bought $949,381 and sold $2.18M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Ciongoli Gregory Austin (director) — $949,381.
The last purchase of 53,407 shares for transaction amount of $499,676 was made by Ciongoli Gregory Austin (director) on 2026‑08‑27.
| 2026-08-27 | Ciongoli Gregory Austin | director | 53,407 0.1032% | $9.36 | $499,676 | -19.64% | ||
| 2026-08-26 | Ciongoli Gregory Austin | director | 49,196 0.0927% | $9.14 | $449,706 | -19.35% | ||
| 2026-07-02 | Sale | PAKOLA STEVE | Chief Medical Officer | 2,161 0.0043% | $13.64 | $29,476 | -32.79% | |
| 2026-07-01 | Sale | PAKOLA STEVE | Chief Medical Officer | 36,725 0.0763% | $12.86 | $472,284 | -31.70% | |
| 2026-06-29 | Sale | PAKOLA STEVE | Chief Medical Officer | 19,608 0.0354% | $11.04 | $216,472 | -22.23% | |
| 2026-05-11 | Sale | PAKOLA STEVE | Chief Medical Officer | 15,309 0.0324% | $11.02 | $168,705 | -18.80% | |
| 2026-03-10 | Sale | PAKOLA STEVE | Chief Medical Officer | 5,124 0.0101% | $10.35 | $53,033 | -12.22% | |
| 2025-10-09 | Sale | Simpson Curran | Chief Executive Officer | 20,811 0.0427% | $12.62 | $262,635 | -18.16% | |
| 2025-09-29 | Sale | Simpson Curran | Chief Executive Officer | 7,624 0.0154% | $10.03 | $76,469 | +3.76% | |
| 2025-09-10 | Sale | Simpson Curran | Chief Executive Officer | 7,734 0.016% | $10.02 | $77,495 | +6.79% | |
| 2025-05-12 | Sale | Mills Kenneth T. | director | 20,602 0.0408% | $7.91 | $163,046 | +17.44% | |
| 2024-10-01 | Sale | KARABELAS ARGERIS N | director | 10,000 0.0191% | $10.11 | $101,052 | -15.28% | |
| 2024-09-03 | Sale | KARABELAS ARGERIS N | director | 10,000 0.0206% | $11.56 | $115,588 | -23.72% | |
| 2024-08-01 | Sale | Simpson Curran | Chief Executive Officer | 100 0.0002% | $15.00 | $1,500 | -34.26% | |
| 2024-08-01 | Sale | KARABELAS ARGERIS N | director | 10,100 0.0208% | $13.51 | $136,454 | -34.26% | |
| 2024-07-29 | Sale | Simpson Curran | Chief Executive Officer | 9,648 0.0205% | $15.04 | $145,106 | -38.75% | |
| 2024-07-29 | Sale | KARABELAS ARGERIS N | director | 11,000 0.0234% | $15.04 | $165,495 | -38.75% | |
| 2024-07-25 | Sale | Mills Kenneth T. | director | 15,369 0.0303% | $13.96 | $214,501 | -38.53% | |
| 2024-07-24 | Sale | Mills Kenneth T. | director | 12,221 0.0251% | $13.78 | $168,433 | -35.15% | |
| 2024-07-17 | Sale | Mills Kenneth T. | director | 2,210 0.0047% | $13.77 | $30,440 | -32.94% |
| Ciongoli Gregory Austin | director | 118035 0.1788% | $900,607.05 | 2 | 0 | |
| Flynn James E | 10 percent owner | 1256542 1.9035% | $9.59M | 1 | 0 | <0.0001% |
$10,154,205 | 103 | -4.60% | $631.34M | |
$40,226,318 | 58 | 18.89% | $539.26M | |
$16,169,789 | 40 | 7.44% | $485.1M | |
$1,344,238 | 38 | 23.07% | $639.18M | |
$2,481,409 | 33 | 201.68% | $455.48M |
| Increased Positions | 89 | +48.9% | 4M | +9.5% |
| Decreased Positions | 77 | -42.31% | 4M | -9.46% |
| New Positions | 28 | New | 1M | New |
| Sold Out Positions | 15 | Sold Out | 713,601 | Sold Out |
| Total Postitions | 194 | +6.59% | 42M | +0.04% |
| Blackrock, Inc. | $86,453.00 | 12.49% | 6.37M | -388,200 | -5.74% | 2025-09-30 |
| Redmile Group, Llc | $63,689.00 | 9.2% | 4.69M | -82,328 | -1.72% | 2025-09-30 |
| Jpmorgan Chase & Co | $54,785.00 | 7.92% | 4.04M | +185,223 | +4.81% | 2025-09-30 |
| Vanguard Group Inc | $45,298.00 | 6.55% | 3.34M | -83,094 | -2.43% | 2025-09-30 |
| State Street Corp | $26,935.00 | 3.89% | 1.98M | +141,233 | +7.66% | 2025-09-30 |
| Goldman Sachs Group Inc | $25,135.00 | 3.63% | 1.85M | +67,708 | +3.79% | 2025-09-30 |
| Morgan Stanley | $23,127.00 | 3.34% | 1.7M | +709,512 | +71.33% | 2025-09-30 |
| Aqr Capital Management Llc | $17,501.00 | 2.53% | 1.29M | +359,459 | +38.64% | 2025-09-30 |
| Geode Capital Management, Llc | $15,274.00 | 2.21% | 1.13M | -2,973 | -0.26% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $14,995.00 | 2.17% | 1.11M | -17,736 | -1.58% | 2025-09-30 |